Personalized Cancer Vaccine Shows Promise After Pancreatic Cancer Surgery | Research

The takeaway

Neoantigen-pulsed dendritic cell vaccines induced immune responses in 81% of pancreatic cancer patients and showed promising survival signals.

81.3%
Of patients developed neoantigen-specific T cell responses after vaccination

What the researchers found

81.3% of patients developed neoantigen-specific immune responses; only 1 of 7 patients receiving adjuvant vaccination had recurrence over 5+ years.

Why it matters

Pancreatic cancer has extremely poor prognosis and resists most immunotherapies. This personalized approach shows early but promising results.

The numbers in context

- 16 patients received the vaccine; 81.3% (13/16) developed neoantigen-specific T cells

- 7 adjuvant patients: only 1 recurrence, no deaths, median follow-up 61 months

- 9 patients treated after recurrence: longer survival with T cell induction vs without

- One case showed a dominant CD4+ T cell clone induced by long peptides

How the study worked

Retrospective study of 16 patients who received personalized neoantigen peptide-pulsed dendritic cell vaccines after pancreatic cancer surgery.

Who was studied

N=16 pancreatic cancer patients who received neoantigen peptide-pulsed DC vaccine after surgery. 7 in adjuvant setting, 9 after recurrence.

What this study cannot tell us

Very small retrospective study without a control group. Cannot establish efficacy without randomized trials.

How to read the evidence

Small retrospective study without control group. Very preliminary evidence but promising signals for a notoriously difficult cancer.

When this study was published

Published in 2025 with follow-up extending to 70 months.

The bigger picture

Personalized cancer vaccines represent a frontier in immunotherapy, and pancreatic cancer is among the most difficult targets where new approaches are desperately needed.

Questions still open

Would these results hold in a randomized controlled trial?
Can this approach be scaled for broader clinical use?
What role does the long-peptide/CD4+ T cell response play?

Common questions

What is a neoantigen vaccine?

A personalized cancer vaccine that uses unique proteins found only on a patient's tumor to train the immune system to attack cancer cells.

Is this available as standard treatment?

Not yet. This is still in early research stages, but the results are promising enough to warrant larger clinical trials.

Read the original research

Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.

Frontiers in immunology, 16, 1571182

View on PubMed ↗Publisher’s paper ↗

Citation

Oyama, Koki; Nakata, Kohei; Abe, Toshiya; Hirotaka, Kento; Fujimori, Nao; Kiyotani, Kazuma; Iwamoto, Chika; Ikenaga, Naoki; Morisaki, Shinji; Umebayashi, Masayo; Tanaka, Hiroto; Koya, Norihiro; Nakagawa, Shinichiro; Tsujimura, Kenta; Yoshimura, Sachiko; Onishi, Hideya; Nakamura, Yusuke; Nakamura, Masafumi; Morisaki, Takashi. (2025). Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.. Frontiers in immunology, 16, 1571182. https://doi.org/10.3389/fimmu.2025.1571182